IFN-α skews monocytes into CD56+-expressing dendritic cells with potent functional activities in vitro and in vivo

Journal of Immunology

Volumn 180, Issue 3, 2008, Pages 1462-1470

  Papewalis, Claudia ^a   Jacobs, Benedikt ^a,b   Wuttke, Margret ^a   Ullrich, Evelyn ^b   Baehring, Thomas ^a   Fenk, Roland ^a   Willenberg, Holger S ^a   Schinner, Sven ^a   Cohnen, Mathias ^a   Seissler, Jochen ^c   Zacharowski, Kai ^d   Scherbaum, Werner A ^a   Schott, Matthias ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b INSERM   (France)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIBODY; CD56 ANTIGEN; CD8 ANTIGEN; CYTOKINE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; LYMPHOCYTE SURFACE MARKER; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADOPTIVE IMMUNOTHERAPY; ADULT; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL INFILTRATION; CELL STRUCTURE; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DRUG MECHANISM; FLUORESCENCE ACTIVATED CELL SORTING; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; INTERFERON PRODUCTION; LONG TERM CARE; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; MALE; METASTASIS; MONOCYTE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SKIN MANIFESTATION; T LYMPHOCYTE; THYROID MEDULLARY CARCINOMA; TREATMENT DURATION; ANTIGEN PRESENTING CELL; CLINICAL TRIAL; CYTOTOXICITY; DRUG EFFECT; IMMUNOLOGY; MEDULLARY CARCINOMA; METABOLISM; THYROID TUMOR; TRANSPLANTATION; VACCINATION;

ANTIGEN-PRESENTING CELLS; ANTIGENS, CD56; CARCINOMA, MEDULLARY; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HUMANS; HYPERSENSITIVITY, DELAYED; INTERFERON-ALPHA; MONOCYTES; THYROID NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; VACCINATION;

EID: 40549135921     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.3.1462     Document Type: Article

References (49)

1. Belardelli, F., and I. Gresser. 1996. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol. Today 17: 369-372.
2. Pfeffer, L. M., C. A. Dinarello, R. B. Herberman, B. R. Williams, E. C. Borden, R. Bordens, M. R. Walter, T. L. Nagabhushan, P. P. Trotta, and S. Pestka. 1998. Biological properties of recombinant α-interferons: 40th anniversary of the discovery of interferons. Cancer Res. 58: 2489-2499.
3. Sun, S., X. Zhang, D. F. Tough, and J. Sprent. 1998. Type I interferon-mediated stimulation of T cells by CpG DNA. J. Exp. Med. 188: 2335-2342.
4. Marrack, P., J. Kappler, and T. Mitchell. 1999. Type I interferons keep activated T cells alive. J. Exp. Med. 189: 521-530.
5. Kolumam, G. A., S. Thomas, L. J. Thompson, J. Sprent, and K. Murali-Krishna. 2005. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J. Exp. Med. 202: 637-650.
6. Trinchieri, G., and D. Santoli. 1978. Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells: enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J. Exp. Med. 147: 1299-1313.
7. Siegal, F. P., N. Kadowaki, M. Shodell, P. A. Fitzgerald-Bocarsly, K. Shah, S. Ho, S. Antonenko, and Y. J. Liu. 1999. The nature of the principal type 1 interferon-producing cells in human blood. Science 284: 1835-1837.
8. Cooper, M. A., T. A. Fehniger, A. Fuchs, M. Colonna, and M. A. Caligiuri. 2004. NK cell and DC interactions. Trends Immunol. 25: 47-52.
9. Gerosa, F., B. Baldani-Guerra, C. Nisii, V. Marchesini, G. Carra, and G. Trinchieri. 2002. Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. 195: 327-333.
10. Piccioli, D., S. Sbrana, E. Melandri, and N. M. Valiante. 2002. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J. Exp. Med. 195: 335-341.
11. Taieb, J., N. Chaput, C. Menard, L. Apetoh, E. Ullrich, M. Bonmort, M. Pequignot, N. Casares, M. Terme, C. Flament, et al. 2006. A novel dendritic cell subset involved in tumor immunosurveillance. Nat. Med. 12: 214-219.
12. Chan, C. W., E. Crafton, H. N. Fan, J. Flook, K. Yoshimura, M. Skarica, D. Brockstedt, T. W. Dubensky, M. F. Stins, L. L. Lanier, et al. 2006. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat. Med. 12: 207-213.
13. + cells identify them as a subset of NK cells. J. Exp. Med. 204: 2561-2568.
14. + interferon-producing killer dendritic cells are activated natural killer cells. J. Exp. Med. 204: 2569-2578.
15. Caminschi, I., F. Ahmet, K. Heger, J. Brady, S. L. Nutt, D. Vremec, S. Pietersz, M. H. Lahoud, L. Schofield, D. S. Hansen, et al. 2007. Putative IKDCs are functionally and developmentally similar to natural killer cells, but not to dendritic cells. J. Exp. Med. 204: 2579-2590.
16. Farag, S. S., and M. A. Caligiuri. 2006. Human natural killer cell development and biology. Blood Rev. 20: 123-137.
17. + β cells by HLA-restricted and non-HLA-restricted pathways. Hum. Immunol. 63: 256-270.
18. Griffith, T. S., S. R. Wiley, M. Z. Kubin, L. M. Sedger, C. R. Maliszewski, and N. A. Fanger. 1999. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J. Exp. Med. 189: 1343-1354.
19. Fanger, N. A., C. R. Maliszewski, K. Schooley, and T. S. Griffith. 1999. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J. Exp. Med. 190: 1155-1164.
20. + progenitors and activated with type I interferon. J. Immunother. 28: 505-516.
21. Schott, M., J. Feldkamp, M. Klucken, G. Kobbe, W. A. Scherbaum, and J. Seissler. 2002. Calcitonin-specific antitumor immunity in medullary thyroid carcinoma following dendritic cell vaccination. Cancer Immunol. Immunother. 51: 663-668.
22. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med. 179: 1109-1118.
23. 2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer 85: 1828-1842.
24. Dauer, M., K. Pohl, B. Obermaier, T. Meskendahl, J. Robe, M. Schnurr, S. Endres, and A. Eigler. 2003. Interferon-α disables dendritic cell precursors: dendritic cells derived from interferon-α-treated monocytes are defective in maturation and T-cell stimulation. Immunology 110: 38-47.
25. + T cell responses against human tumor antigens. J. Immunol. 172: 5363-5370.
26. Kayagaki, N., N. Yamaguchi, M. Nakayama, H. Eto, K. Okumura, and H. Yagita. 1999. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 189: 1451-1460.
27. Zamai, L., M. Ahmad, I. M. Bennett, L. Azzoni, E. S. Alnemri, and B. Perussia. 1998. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J. Exp. Med. 188: 2375-2380.
28. Yamamoto, T., H. Nagano, M. Sakon, H. Wada, H. Eguchi, M. Kondo, B. Damdinsuren, H. Ota, M. Nakamura, H. Wada, et al. 2004. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-α/5-fluorouracil against hepatocellular carcinoma. Clin. Cancer Res. 10: 7884-7895.
29. Mohty, M., A. Vialle-Castellano, J. A. Nunes, D. Isnardon, D. Olive, and B. Gaugler. 2003. IFN-α skews monocyte differentiation into Toll-like receptor 7-expressing dendritic cells with potent functional activities. J. Immunol. 171: 3385-3393.
30. Paquette, R. L., N. C. Hsu, S. M. Kiertscher, A. N. Park, L. Tran, M. D. Roth, and J. A. Glaspy. 1998. Interferon-α and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J. Leukocyte Biol. 64: 358-367.
31. Santini, S. M., C. Lapenta, M. Logozzi, S. Parlato, M. Spada, T. Di Pucchio, and F. Belardelli. 2000. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J. Exp. Med. 191: 1777-1788.
32. Luft, T., P. Luetjens, H. Hochrein, T. Toy, K. A. Masterman, M. Rizkalla, C. Maliszewski, K. Shortman, J. Cebon, and E. Maraskovsky. 2002. IFN-α enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells. Int. Immunol. 14: 367-380.
33. Brigl, M., and M. B. Brenner. 2004. CD1: antigen presentation and T cell function. Annu. Rev. Immunol. 22: 817-890.
34. de Saint-Vis, B., J. Vincent, S. Vandenabeele, B. Vanbervliet, J. J. Pin, S. It-Yahia, S. Patel, M. G. Mattei, J. Banchereau, S. Zurawski, et al. 1998. A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartment. Immunity 9: 325-336.
35. Parlato, S., S. M. Santini, C. Lapenta, T. Di Pucchio, M. Logozzi, M. Spada, A. M. Giammarioli, W. Malorni, S. Fais, and F. Belardelli. 2001. Expression of CCR-7, MIP-3β, and Th-1 chemokines in type I IFN- induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood 98: 3022-3029.
36. Mailliard, R. B., A. Wankowicz-Kalinska, Q. Cai, A. Wesa, C. M. Hilkens, M. L. Kapsenberg, J. M. Kirkwood, W. J. Storkus, and P. Kalinski. 2004. α-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 64: 5934-5937.
37. Hamerman, J. A., K. Ogasawara, and L. L. Lanier. 2005. NK cells in innate immunity. Curr. Opin. Immunol. 17: 29-35.
38. Moretta, A. 2002. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat. Rev. Immunol. 2: 957-964.
39. + myelin-reactive T cells lyses target cells expressing CD56/neural cell adhesion molecule. J. Immunol. 157: 679-688.
40. Takasaki, S., K. Hayashida, C. Morita, H. Ishibashi, and Y. Niho. 2000. CD56 directly interacts in the process of NCAM-positive target cell-killing by NK cells. Cell Biol. Int. 24: 101-108.
41. Lu, L., S. Qian, P. A. Hershberger, W. A. Rudert, D. H. Lynch, and A. W. Thomson. 1997. Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation. J. Immunol. 158: 5676-5684.
42. Huang, J., T. Tatsumi, E. Pizzoferrato, N. Vujanovic, and W. J. Storkus. 2005. Nitric oxide sensitizes tumor cells to dendritic cell-mediated apoptosis, uptake, and cross-presentation. Cancer Res. 65: 8461-8470.
43. Janjic, B. M., G. Lu, A. Pimenov, T. L. Whiteside, W. J. Storkus, and N. L. Vujanovic. 2002. Innate direct anticancer effector function of human immature dendritic cells. I. Involvement of an apoptosis-inducing pathway. J. Immunol. 168: 1823-1830.
44. 2, Fas ligand, and TNF-related apoptosis-inducing ligand. J. Immunol. 168: 1831-1839.
45. Stary, G., C. Bangert, M. Tauber, R. Strohal, T. Kopp, and G. Stingl. 2007. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J. Exp. Med. 204: 1441-1451.
46. Moretta, L., and A. Moretta. 2004. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J. 23: 255-259.
47. Yamaguchi, N., Y. Fujimori, Y. Fujibayashi, I. Kasumoto, H. Okamura, K. Nakanishi, and H. Hara. 2005. Interferon-γ production by human cord blood monocyte-derived dendritic cells. Ann. Hematol. 84: 423-428.
48. Fricke, I., D. Mitchell, J. Mittelstadt, N. Lehan, H. Heine, T. Goldmann, A. Bohle, and S. Brandau. 2006. Mycobacteria induce IFN-γ production in human dendritic cells via triggering of TLR2. J. Immunol. 176: 5173-5182.
49. + T cells and monocyte/dendritic cell precursors. Cancer Res. 66: 4943-4951.